Hemolytic disease of the fetus and newborn: epidemiology, antibody profile, and clinical outcomes from universal direct antiglobulin test screening. A retrospective study from Saudi Arabia

Background HDFN is a significant cause of newborn mortality. This study aimed to identify the frequency of primary alloantibodies responsible for HDFN and evaluate associated clinical outcomes at a tertiary care hospital in Riyadh, Saudi Arabia. Methods This retrospective study analyzed 4,340 newborns. Direct antiglobulin test (DAT)-positive cases were evaluated. Lui freeze-thaw elution and acid elution procedures were used to detect specific ABO and Rh incompatibilities, respectively. Lui freeze-thaw elution was used for ABO antibody detection due to the labile nature of anti-A/anti-B binding, while acid elution was used for Rh and other non-ABO antibodies due to its higher sensitivity for IgG-mediated sensitization. Clinical outcomes including hyperbilirubinemia, Neonatal Intensive Care Unit (NICU) admission, and red blood cell (RBC) transfusions were evaluated. Results Out of 4,340 newborns, 267 (6.1%) tested DAT-positive. Among these, ABO incompatibility was the most frequent finding (76%, n = 204), primarily blood type B antibodies ( n = 106). Suspected Rh incompatibility accounted for 23.5% ( n = 63), with confirmed Rh antibody-mediated cases comprising 54 (20.2%) of the DAT-positive cohort; anti-D was the most frequent antibody ( n = 28). The remaining nine cases (3.4%) were classified as suspected Rh incompatibility with negative eluate. Clinically significant non-ABO antibodies, including anti-E ( n = 7) and anti-c ( n = 5), were also identified. Hyperbilirubinemia was the main clinical complication, affecting 44% of the DAT-positive cohort. The background rate of hyperbilirubinemia in the DAT-negative cohort was not systematically extractable; therefore, the clinical significance of the 44% rate cannot be fully determined and should be interpreted with caution. Despite this, clinical outcomes were generally mild: 61% of infants did not require NICU admission, and only 4.1% of DAT-positive newborns ( n = 11) required RBC transfusions. Conclusion ABO incompatibility was the main cause of HDFN at KFMC, generally resulting in favorable clinical outcomes. Future studies should evaluate whether a maternal-targeted selective DAT screening strategy, paired with comprehensive prenatal antibody profiling, could optimize resources while maintaining safety. However, this is a hypothesis-generating proposition based on our single-center data; direct comparative studies evaluating universal vs. selective screening strategies are needed before any policy changes are implemented. Future multi-center studies are recommended to confirm these findings in the Kingdom.

Authors

Institutions

Publication Details

Journal
Frontiers in Medicine
Published
2026-11-18
DOI
https://doi.org/10.3389/fmed.2026.1921820
Primary Topic
Blood groups and transfusion
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Hemolytic disease of the fetus and newborn: epidemiology, antibody profile, and clinical outcomes from universal direct antiglobulin test screening. A retrospective study from Saudi Arabia

Ammar Hasan Alsughayir, Alyazeed S. Alsaif, Muhammad Raihan Sajid, Mohammed Khalid Alkhalifah et al.
2 links
Frontiers in Medicine
Blood groups and transfusion
article

Hemolytic disease of the fetus and newborn: epidemiology, antibody profile, and clinical outcomes from universal direct antiglobulin test screening. A retrospective study from Saudi Arabia

Ammar Hasan Alsughayir, Alyazeed S. Alsaif, Muhammad Raihan Sajid, Mohammed Khalid Alkhalifah, Salman Aldosari, Sarah Bakr Abobakr, Rasha M. Khayata, Jana H. Husein, Yazeed Abdullah Alfalah, Sara Alkahwaji, Haifa Alhowaidi
article en

Abstract

Background HDFN is a significant cause of newborn mortality. This study aimed to identify the frequency of primary alloantibodies responsible for HDFN and evaluate associated clinical outcomes at a tertiary care hospital in Riyadh, Saudi Arabia. Methods This retrospective study analyzed 4,340 newborns. Direct antiglobulin test (DAT)-positive cases were evaluated. Lui freeze-thaw elution and acid elution procedures were used to detect specific ABO and Rh incompatibilities, respectively. Lui freeze-thaw elution was used for ABO antibody detection due to the labile nature of anti-A/anti-B binding, while acid elution was used for Rh and other non-ABO antibodies due to its higher sensitivity for IgG-mediated sensitization. Clinical outcomes including hyperbilirubinemia, Neonatal Intensive Care Unit (NICU) admission, and red blood cell (RBC) transfusions were evaluated. Results Out of 4,340 newborns, 267 (6.1%) tested DAT-positive. Among these, ABO incompatibility was the most frequent finding (76%, n = 204), primarily blood type B antibodies ( n = 106). Suspected Rh incompatibility accounted for 23.5% ( n = 63), with confirmed Rh antibody-mediated cases comprising 54 (20.2%) of the DAT-positive cohort; anti-D was the most frequent antibody ( n = 28). The remaining nine cases (3.4%) were classified as suspected Rh incompatibility with negative eluate. Clinically significant non-ABO antibodies, including anti-E ( n = 7) and anti-c ( n = 5), were also identified. Hyperbilirubinemia was the main clinical complication, affecting 44% of the DAT-positive cohort. The background rate of hyperbilirubinemia in the DAT-negative cohort was not systematically extractable; therefore, the clinical significance of the 44% rate cannot be fully determined and should be interpreted with caution. Despite this, clinical outcomes were generally mild: 61% of infants did not require NICU admission, and only 4.1% of DAT-positive newborns ( n = 11) required RBC transfusions. Conclusion ABO incompatibility was the main cause of HDFN at KFMC, generally resulting in favorable clinical outcomes. Future studies should evaluate whether a maternal-targeted selective DAT screening strategy, paired with comprehensive prenatal antibody profiling, could optimize resources while maintaining safety. However, this is a hypothesis-generating proposition based on our single-center data; direct comparative studies evaluating universal vs. selective screening strategies are needed before any policy changes are implemented. Future multi-center studies are recommended to confirm these findings in the Kingdom.

Frontiers in MedicineVol. 13
Alfaisal University (SA), Qassim University (SA), King Fahd Medical City (SA)
Good health and well-being
Blood groups and transfusion
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon